SuperworthCapricor Therapeutics market cap CAPR
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $344.8M
- Highest close in our data
- $2B
- Apr 2026
Capricor Therapeutics is worth $344.8M at the close on Oct 23, 2026, at $5.93 a share.
That is up 22% over the last year and up 303% over five years.
Its highest close in our data was $2B in Apr 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $344.8M | $223M | $2B | −75% |
| 2025 | $1.4B | $244.6M | $1.4B | +112% |
| 2024 | $640.2M | $111.2M | $864.4M | +325% |
| 2023 | $150.6M | $70.1M | $200.3M | +55% |
| 2022 | $97.4M | $69.8M | $151.9M | +38% |
| 2021 | $70.8M | $69.8M | $153.4M | +1% |
| 2020 | $70.1M | $4.5M | $122.1M | +1324% |
| 2019 | $4.9M | $4.5M | $20.8M | −57% |
| 2018 | $11.5M | $11.5M | $53.7M | −72% |
| 2017 | $40.6M | $14.2M | $72.3M | −29% |
| 2016 | $56.9M | $34.1M | $80.1M | +14% |
| 2015 | $49.9M | $41.4M | $156.5M | +15% |
| 2014 | $43.4M | $3M | $84.8M | +1509% |
| 2013 | $2.7M | $1.3M | $6.9M | +109% |
| 2012 | $1.3M | $1.3M | $22.2M | −94% |
| 2011 | $21.8M | $19.9M | $26.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Capricor Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| CAPRCapricor Therapeutics | $344.8M |
| ARVNArvinas | $477.3M |
| NATRNatures Sunshine Products | $213.8M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Capricor Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.